Health and Fitness Health and Fitness
Mon, March 12, 2012
Sat, March 10, 2012
Fri, March 9, 2012
Thu, March 8, 2012
Wed, March 7, 2012
Tue, March 6, 2012
[ Tue, Mar 06th 2012 ] - Market Wire
Verotoxin and E. coli 0157
Mon, March 5, 2012
[ Mon, Mar 05th 2012 ] - Market Wire
Sienna Gold Warrants Extended
[ Mon, Mar 05th 2012 ] - Market Wire
30 a.m. ET
Fri, March 2, 2012
Thu, March 1, 2012
Wed, February 29, 2012
Tue, February 28, 2012
[ Tue, Feb 28th 2012 ] - Market Wire
Alere to Acquire eScreen, Inc.
[ Tue, Feb 28th 2012 ] - Market Wire
ICON Acquires PriceSpective
Mon, February 27, 2012

Isis Pharmaceuticals to Present at the 24th Annual ROTH Conference


//health-fitness.news-articles.net/content/2012/ .. -present-at-the-24th-annual-roth-conference.html
Published in Health and Fitness on Monday, March 5th 2012 at 4:45 GMT by Market Wire   Print publication without navigation


Isis Pharmaceuticals to Present at the 24th Annual ROTH Conference -- CARLSBAD, Calif., March 5, 2012 /PRNewswire/ --

Isis Pharmaceuticals to Present at the 24th Annual ROTH Conference

[ ]

CARLSBAD, Calif., March 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: [ ISIS ]), the leader in antisense therapeutics, today announced that management will present a company overview at ROTH's 24th Annual OC Growth Stock Conference on Monday, March 12, 2012 at 9:30 a.m. PT at the Ritz-Carlton Laguna Niguel.  

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, [ www.isispharm.com ].  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at [ www.isispharm.com ].

SOURCE Isis Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.isispharm.com ]


Publication Contributing Sources